The exercise period for warrants of series TO1 begins today

Report this content

Today, on September 15, 2021, the exercise period begins for warrants of series TO1 in Cereno Scientific AB (publ) (“Cereno” or the “Company”). The exercise period runs until September 29, 2021. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share of series B in the Company at a price of SEK 2.85 per share. If all warrants of series TO1 are exercised, the Company will receive approximately SEK 98.4 million before issue costs. In order for the warrants not to expire without value, it is required that the holder subscribes for shares no later than September 29, 2021, or alternatively sells the warrants no later than September 27, 2021.

Summarized terms for the warrants of series TO1:          

Exercise period: September 15, 2021 – September 29, 2021.

Exercise price: SEK 2.85 per share of series B.

Issue size: 34,519,281 warrants of series TO1. If all the warrants are exercised, 34,519,281 shares of series B are issued, and the Company will receive approximately SEK 98.4 million before issuing costs.

Last day for trading with warrants of series TO1: September 27, 2021.

Note that the warrants that are not exercised at latest on September 29, 2021, or sold at the latest on September 27, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please observe that certain nominees might close their application earlier than September 29, 2021.

Full terms an conditions for the warrants are available at the Company's website,, and Mangold’s website,

How to excersice the warrants:

Nominee-registered warrants (custody):

Subscription and payment through the exercise of the warrants shall take place in accordance with instructions from the respective nominee. Please contact your nominee for further information.

Directly registered warrants (VP ​​account):

No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at the Swedish Companies Registration Office.

The application form with instructions for payment will be available on the Company's website,, and on the issue institute Mangold Fondkommission AB's website,

Mangold Fondkommission AB is financial adviser and issuing agent and MAQS Advokatbyrå AB is legal advisor to Cereno in connection with the exercise of the warrants of series TO1.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595


For more information regarding Cereno, please contact:

Daniel Brodén, CFO

Cell: +46 768 66 77 87


About Cereno Scientific

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca's BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on


Documents & Links